"The data show that in patients hospitalised with Covid-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death," Peter Horby, professor of emerging infectious diseases in the Nuffield Department of Medicine at the University of Oxford, and joint chief investigator for the RECOVERY trial, said of the study.

"Although aspirin was associated with a small increase in the likelihood of being discharged alive this does not seem to be sufficient to justify its widespread use for patients hospitalised with Covid-19.".

Martin Landray, a professor of medicine and epidemiology at the Nuffield Department of Population Health at the University of Oxford and one of the chief investigators in the study, described the results as "disappointing.".